Evidence map›Paper›PMID 32200442›Full record

ReviewCurrent oncology reports2020

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.

Eli P Darnell, Meghan J Mooradian, Erez N Baruch, Melis Yilmaz, Kerry L Reynolds

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eli P DarnellDivision of Internal Medicine, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA.
Meghan J MooradianDivision of Medical Oncology, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA.
Erez N BaruchElla Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Melis YilmazHarvard Medical School, Boston, MA, USA.
Kerry L ReynoldsDivision of Medical Oncology, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA. kreynolds7@partners.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewWhile immune checkpoint inhibitor (ICI) therapy has improved melanoma patient outcomes, it has also resulted in the rise of unique immune-related adverse events (irAEs). Here, we review and synthesize irAE management recommendations from several oncological societies into a streamlined format to aid in diagnosis and management. We also include clinical pearls highlighting several recent research studies in this field. RECENT

findingsKnowledge of immunotherapy toxicity has continually evolved, and several major oncologic societies have recently released new or updated guidelines. Keeping up with the evolving field of immunotherapy and related toxicities is crucial, because ICI use, in combination with other agents, will only continue to increase and likely result in new and different patterns of irAEs. Providing clear and concise references for clinicians will help ensure proper irAE evaluation and management going forward. We present one such reference here, covering management of common and/or serious irAEs.

Indexed as

Practice Guidelines as TopicAntineoplastic Agents, ImmunologicalCTLA-4 AntigenDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsIpilimumabMelanomaNivolumabProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalCTLA-4 AntigenImmune Checkpoint InhibitorsIpilimumabNivolumabProgrammed Cell Death 1 ReceptorAnti-CTLA-4Anti-PD-1ColitisDiabetesHepatitisHypophysitisHypothyroidismICI-induced toxicityImmune-related adverse eventImmunosuppressionImmunotherapyIpilimumabirAEMelanomaMyocarditisNivolumabPembrolizumabPneumonitisSteroidsToxicity

Identifiers

PMID32200442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.